CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I Dose Escalation Trial of CD19 Directed Chimeric Antigen Receptor T Cell Therapy in the Treatment of Relapsed/Refractory B Cell Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04892277
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:38.501394+00:00
Published At: 2025-07-01T00:00:00+00:00
Record Updated At: 2025-07-01
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Small Lymphocytic Lymphoma", "Recurrent Transformed Chronic Lymphocytic Leukemia", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Small Lymphocytic Lymphoma", "Refractory Transformed Chronic Lymphocytic Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-07-01"
protocolSection.identificationModule.nctId: "NCT04892277"
protocolSection.identificationModule.officialTitle: "Phase I Dose Escalation Trial of CD19 Directed Chimeric Antigen Receptor T Cell Therapy in the Treatment of Relapsed/Refractory B Cell Malignancies"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.